Market research
SNG.LSE Synairgen plc
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 12M
- P/E ratio
- Not available
- Analyst target
- 8
- Dividend yield
- Not available
- Beta
- -2.23
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00B0381Z20
- Market cap
- 12M
- P/E ratio
- Not available
- Analyst target
- 8
- Dividend yield
- Not available
- Beta
- -2.23
About
About Synairgen plc
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SNG.LSE discussion.
5 years, 4 months ago
Synairgen plc is currently in a long term uptrend where the price is trading 4.8% above its 200 day moving average.
From a valuation standpoint, the stock is 70.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 759.0.
Based on the above factors, Synairgen plc gets an overall score of 1/5.